Article
Characterization of covalent inhibitors that disrupt the interaction between the tandem…
medRxiv · 2023 · Bashore, F. M.; Katis, V. L.; Du, Y.; Sikdar, A.; Wang, D.; Bradshaw, W. J.; Rygiel, K. A.; Leisner, T. M.; Chalk, R.; Mishra, S.; Williams, A. C.; Gileadi, O.; Brennan, P. E.; Wiley, J. C.; Gockley, J.; Cary, G. A.; Carter, G. W.; Young, J. E.; Pearce, K. H.; Fu, H.; the Emory-Sage-SGC TREAT-AD Center,; Axtman, A. D.
Key facts
| Title | Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM |
|---|---|
| First author | Bashore, F. M.; Katis, V. L.; Du, Y.; Sikdar, A.; Wang, D.; Bradshaw, W. J.; Rygiel, K. A.; Leisner, T. M.; Chalk, R.; Mishra, S.; Williams, A. C.; Gileadi, O.; Brennan, P. E.; Wiley, J. C.; Gockley, J.; Cary, G. A.; Carter, G. W.; Young, J. E.; Pearce, K. H.; Fu, H.; the Emory-Sage-SGC TREAT-AD Center, ; Axtman, A. D. |
| Journal | medRxiv |
| Published | Jul 31, 2023 |
| DOI | 10.1101/2023.07.28.551026 |
| Devices mentioned | K013842, K073487, K073490, K202641, K231013, K963139, K982714, K983345, K983715, K992228 |
| Product codes mentioned | CFN, DDD, DDG, JJQ, JPK, PPM, QBD |
At a glance
- 10–99 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1